This study evaluates the cost-effectiveness of the MAR-HF-Titration telemedicine programme, implemented at Hospital del Mar for patients with heart failure with reduced ejection fraction (HFrEF). A pre-post retrospective cost-effectiveness analysis was conducted using data from 208 patients enrolled between 2021 and 2023. Effectiveness was estimated by constructing individual pre- and post-intervention QALYs based on literature-derived utility values. Cost data were obtained from hospital administrative records at the patient level. Paired t-tests were performed, and costs and QALYs were modelled using gamma and beta distributions for probabilistic sensitivity analysis. A sensitivity analysis excluding newly diagnosed patients was also conducted. The programme was associated with a 52% reduction in total healthcare costs (€4,771.79 per patient), mainly driven by a reduction of the heart failure-related intervention costs, which accounted for 88% of total costs and decreased by 58% in the post-intervention period (€4,384.97 per patient). This reduction was also associated with a substantial decrease in length of stay during the post-intervention period, with a 76.63% reduction in total hospitalisations and an 82.34% reduction in hospitalisations related to heart failure. The effectiveness analysis showed an increase of 0.0298 QALYs per patient during the six-month intervention period. Similar outcomes were observed for non-newly diagnosed patients.
Spain leads the world in organ donation, and the 40th anniversary of its first liver transplant was recently commemorated. Our aim was to evaluate the evolution of the Liver Transplantation (LT) program in Spain over its four decades (1984–2024), examining clinical outcomes and societal economic benefits within a mature transplantation framework. Standardized national data from the Organización Nacional de Trasplantes and the Sociedad Española de Trasplante Hepático were used to reconstruct recipient cohorts by age group. Patient survival was estimated using Kaplan–Meier analysis. An economic evaluation from a societal perspective integrated surgical costs, long-term immunosuppressive therapy, and productivity gains associated with recipients’ participation in the labour market. LT activity increased steadily during the initial expansion of the program and has stabilised at approximately 1,200 procedures per year over the past two decades. Both donor and recipient populations have aged; there are currently more patients over 60 years of age than two decades ago. Survival improved throughout the study period, extending life expectancy despite variations related to underlying disease. From an economic perspective, annual surgical costs remained below €60 million, increasing to €70–90 million when long-term immunosuppressive therapy was included. The economic contribution of surviving recipients to the labour market increased steadily, exceeding €75 million in 2024 and resulting in a positive balance since the early 2010s. Adult recipients generated net economic benefits, whereas paediatric recipients showed delayed but progressively increasing contributions as they entered the workforce. LT in Spain has produced sustained improvements in expected survival while generating substantial societal value, demonstrating that LT is both an effective clinical intervention and a valuable public health investment. The Spanish liver transplantation system may serve as a benchmark for evaluating the sustainability and societal impact of liver transplant programs in other healthcare systems.